CASBF Stock CANSINO BIOLOGICS (CASBF, $4.62) RSI Indicator left the overbought zone on July 17, 2025

GET DAILY SIGNALS

Get AI intraday signals

CASBF - CANSINO BIOLOGICS INC

RSI signal

View

Odds of DOWN Trend

Price: $4.62

Daily change: +$1.42 (+44.28%)

Daily volume: 643

Capitalization: $1.7B

Industry: Pharmaceuticals: Other

CASBF's RSI Oscillator is sitting in overbought zone for 21 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

CASBF broke above its upper Bollinger Band on August 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The 50-day moving average for CASBF moved above the 200-day moving average on August 07, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 109 cases where CASBF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.263) is normal, around the industry mean (16.657). P/E Ratio (0.000) is within average values for comparable stocks, (72.172). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.696). CASBF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (13.441) is also within normal values, averaging (40.190).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CASBF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CASBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.